Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P9BT
|
|||
| Former ID |
DCL000420
|
|||
| Drug Name |
Alicaforsen
|
|||
| Synonyms |
Alicaforsen [INN]; ISIS 2302; ISIS-2302; Intercellular adhesion molecule-1 antisense oligodeoxynucleotide; DNA, d((R)-P-thio)(G-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A); Deoxyribonucleic acid, d((R)-P-thio)(G-C-C-C-A-A-G-C-T-G-G-C-A-T-C-C-G-T-C-A)
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Lleum inflammation [ICD-11: 1A40.0; ICD-10: K91.8] | Phase 3 | [1] | |
| Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9] | Phase 2 | [2] | ||
| Ulcerative colitis [ICD-11: DD71] | Phase 2 | [2] | ||
| Therapeutic Class |
Antisense
|
|||
| Company |
ISIS & Atlantic Healthcare
|
|||
| Structure |
 |
Download2D MOL |
||
| Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)([O-])OC3CC(OC3COP(=S)([O-])OC4CC(OC4COP(=S)([O-])OC5CC(OC5COP(=S)([O-])OC6CC(OC6COP(=S)([O-])OC7CC(OC7COP(=S)([O-])OC8CC(OC8COP(=S)([O-])OC9CC(OC9COP(=S)([O-])OC1CC(OC1CO)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C(N=CN=C21)N)N1C=NC2=C1N=C(NC2=O)N)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)OP(=S)([O-])OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=C(C(=O)NC1=O)C)OP(=S)([O-])OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=S)([O-])OCC1C(CC(O1)N1C=NC2=C(N=CN=C21)N)O
|
|||
| CAS Number |
CAS 185229-68-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||
| REF 3 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.